Eric Siemers

Company: Acumen Pharmaceuticals

Job title: Chief Medical Officer

Seminars:

Panel Discussion: How Will Diagnostics Change With the NIA-AA Revised Criteria for Diagnosis & Staging of Alzheimer’s Disease? 5:30 pm

Shifting Alzheimer’s Disease definitions to more biological than clinical definitions Integrating the latest validated findings in plasma-based marker research to establish likelihood of developing AD Exploring how the novel staging might affect diagnosis and staging to understand the potential impact on clinical researchRead more

day: Conference Day One

Effect of ACU193, an Aβ Oligomer Targeting Monoclonal Antibody, on CSF & Plasma Biomarkers of Alzheimer’s Disease 4:00 pm

Discussing ACU193’s reduction of ARIA in patients with ApoE4 variants without targeting plaque following the INTERCEPT-AD trial Identifying CSF & plasma biomarkers and exploring the differences and approaches with this target Using a bioanalytical target engagement approach to inform dosing and adaptive trial design for phase 2/3 studiesRead more

day: Conference Day One